4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-25-000008
PRESIDENT AND CFO sold 8,000 shares at an average $86.51 ($692,101)
- PRESIDENT AND CFO acquired 8,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2025-01-21 | Option exercise 10b5-1 | +8,000 | $5.35 | $42,800 | 117,491 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2025-01-21 | Sale 10b5-1 | −5,318 | $86.08 | $457,795 | 112,173 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2025-01-21 | Sale 10b5-1 | −1,999 | $87.25 | $174,407 | 110,174 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2025-01-21 | Sale 10b5-1 | −683 | $87.70 | $59,899 | 109,491 | D |
| Derivatives | |||||||
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2025-01-21 | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 254,827 | D | ||
| Open-market sales · 8,000 sh · avg $86.51 · $692,101 | |||||||
Loading xslF345X05/wk-form4_1737587924.xml…